Ruxolitinib (Jakafi or Jakavi) is a licensed, orally administered JAK1/JAK2 inhibitor used to treat neoplastic diseases, particularly myelofibrosis (Harrison et al., 2012; Verstovsek et al., 2012). The gene discussed is JAK1; the disease is myelofibrosis.